Systemic Chemotherapy Interferes in Homocysteine Metabolism in Breast Cancer Patients
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
JOHN WILEY & SONS INC
Autores
YAMASHITA, Eliana K.
TEIXEIRA, Bianca M.
YOSHIHARA, Renata N.
ALVES, Beatriz C. A.
GEHRKE, Flavia S.
VILAS-BOAS, Viviane A.
CORREIA, Joao A.
AZZALIS, Ligia A.
JUNQUEIRA, Virginia B. C.
Citação
JOURNAL OF CLINICAL LABORATORY ANALYSIS, v.28, n.2, p.157-162, 2014
Resumo
Background Hyperhomocysteinemia in breast cancer (BC) patients can be a risk factor for thromboembolic events. This study aimed to evaluate homocysteine and its cofators (folic acid and vitamin B12) concentrations and platelet count at diagnosis of BC, 3 and 6 months after the beginning of chemotherapy treatment and to correlate them with clinical data. Methods Thirty-five BC patients were included; blood samples were obtained by venipuncture. Plasmatic Hcy and cofactors concentrations were measured by competitive chemiluminescent enzyme immunoassay method. Platelet count was done using an automated analyzer. Statistical analysis was performed using the software SPSS. Results During chemotherapy, homocysteine (P = 0.032) and vitamin B12 (P < 0.001) concentrations increased, while folate and platelets decreased (P < 0.001). Among the clinical data, the menopausal status showed significant positive correlation (P = 0.022) with homocysteine concentration increase. Conclusions Evaluation of homocysteine concentrations during chemotherapy is extremely important because their levels increase during chemotherapy treatment, thus increasing the risk of thromboembolism development.
Palavras-chave
homocysteine, folic acid, vitamin B 12, breast neoplasms, chemotherapy and thromboembolism
Referências
- Arkel YS, 2000, SEMIN ONCOL, V27, P362
- Aziz DC., 1999, INTERPRETATION LAB T, P17
- Braun S, 2001, J CLIN ONCOL, V19, P1468
- Chou YC, 2007, BREAST CANCER RES TR, V101, P199, DOI 10.1007/s10549-006-9278-9
- DeStefano V, 1996, BLOOD, V87, P3531
- DONATI MB, 1994, HAEMOSTASIS, V24, P128
- FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802
- Gascon TM, 2010, EINSTEIN, V8, P187
- Gatt A, 2007, INT J LAB HEMATOL, V29, P421, DOI 10.1111/j.1751-553X.2007.00907.x
- Green KB, 1996, HEMATOL ONCOL CLIN N, V10, P499, DOI 10.1016/S0889-8588(05)70349-X
- Instituto Nacional do Cancer, 2012, EST 2012 INC CANC BR
- International Agency for Research on Cancer, GLOBOCAN 2008
- Jeit JA, 2002, ARCH INTERN MED, V162, P1245
- Kakkar AK, 2001, THROMB HAEMOSTASIS, V86, ps732
- LIEBERMAN J, 1961, JAMA-J AM MED ASSOC, V177, P542
- Mego M, 2009, BRIT J CANCER, V101, P1813, DOI 10.1038/sj.bjc.6605413
- Morganti M, 2002, BIOMED PHARMACOTHER, V56, P317, DOI 10.1016/S0753-3322(02)00242-1
- Neufeld EJ, 1998, HEMATOL ONCOL CLIN N, V12, P1193, DOI 10.1016/S0889-8588(05)70049-6
- Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
- SAPHNER T, 1991, J CLIN ONCOL, V9, P286
- Stathopoulou A, 2002, J CLIN ONCOL, V20, P3404, DOI 10.1200/JCO.2002.08.135
- Swaby RF, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-43
- Van Cott EM, 1998, HEMATOL ONCOL CLIN N, V12, P1141, DOI 10.1016/S0889-8588(05)70047-2
- White RH, 2003, THROMB HAEMOSTASIS, V90, P446, DOI 10.1160/TH03-03-0152
- You FL, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-2